Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies ...
CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...
The MarketWatch News Department was not involved in the creation of this content. -- Scemblix(R) is first to show superior efficacy and a favourable safety and tolerability profile in a Phase III ...
FOSTER CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...
MONTREAL, Dec. 10, 2025 /CNW/ - Novartis Canada is pleased to announce that Scemblix ® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario's new Funding ...
Preclinical data shows TERN-701's superior potency against CML resistance mutations; early clinical trial results indicate promising patient responses. Terns Pharmaceuticals announced promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback